E2F8 is a member of the E2F transcription factor family that plays critical roles in regulating cell cycle progression, DNA replication, and cellular proliferation. First identified as an atypical E2F family member, E2F8 has emerged as an important transcriptional repressor that controls cell cycle exit and genomic stability[1][2]. Unlike classical E2F transcription factors that primarily function as activators of cell cycle progression, E2F8 acts predominantly as a transcriptional repressor, forming a distinct subclass of atypical E2F proteins that also includes E2F7[3].
The E2F family consists of eight members (E2F1-8) in mammals, which can be broadly categorized into typical activators (E2F1-5) and atypical repressors (E2F7, E2F8). Typical E2Fs contain a DNA-binding domain and a marked box, while atypical members lack the marked box but retain DNA-binding capability. This structural difference underlies their distinct functions: typical E2Fs primarily activate transcription in cooperation with dimerization partners (DP), while atypical E2Fs function as transcriptional repressors that can form homodimers or heterodimers to control gene expression independently of DP proteins[4][5].
| Property | Value |
|---|---|
| Gene Symbol | E2F8 |
| Full Name | E2F Transcription Factor 8 |
| Chromosomal Location | 11p15.4 |
| NCBI Gene ID | 79733 |
| OMIM ID | 614836 |
| Ensembl ID | ENSG00000156221 |
| UniProt ID | Q0VXJ8 |
| Encoded Protein | E2F transcription factor 8 |
| Protein Family | E2F transcription factor family |
| Associated Diseases | Cancer, Neurodegeneration |
E2F8 is a nuclear protein of approximately 659 amino acids with a molecular weight of about 73 kDa. The protein contains several functional domains:
DNA-binding domain: Located at the N-terminus, this domain enables E2F8 to bind specifically to E2F consensus sequences (TTTSSCGC, where S = G or C) in the promoter regions of target genes. Unlike typical E2Fs, E2F8 can bind DNA as both a homodimer and heterodimer with E2F7[5:1].
Dimerization domain: E2F8 can form both homodimers (E2F8/E2F8) and heterodimers (E2F8/E2F7), enabling diverse DNA-binding configurations and gene regulatory functions. This dimerization capability is crucial for its repressor activity.
Transcription repression domain: The C-terminal region contains domains that recruit co-repressor complexes and mediate transcriptional repression of target genes.
Nuclear localization signal (NLS): E2F8 contains NLS sequences that ensure its proper nuclear localization, which is essential for its function as a transcription factor.
E2F8 functions primarily as a transcriptional repressor, distinguishing it from most other E2F family members that serve as transcriptional activators[4:1]. The repression mechanism involves:
Direct DNA binding: E2F8 binds to E2F consensus sites in the promoters of target genes, preventing activator E2Fs (particularly E2F1, E2F2, and E2F3a) from accessing these sites.
Competition with activator E2Fs: By occupying E2F binding sites, E2F8 competitively inhibits the binding of transcriptional activator E2Fs, effectively silencing E2F-responsive genes.
Recruitment of co-repressors: E2F8 can recruit chromatin-modifying enzymes and co-repressor complexes to target gene promoters, establishing a repressive chromatin state.
Formation of repression complexes: E2F8 works in concert with E2F7 to form specialized repression complexes that maintain transcriptional silencing during S, G2, and M phases of the cell cycle.
E2F8 plays a crucial role in controlling cell cycle progression through multiple mechanisms[6]:
G1/S transition regulation: E2F8 represses genes required for S-phase entry, including DNA replication factors (CDC6, MCM proteins), nucleoside biosynthesis enzymes, and cell cycle regulators. This prevents premature S-phase entry.
S-phase progression: During S-phase, E2F8 continues to repress DNA replication-related genes to ensure orderly DNA synthesis and prevent replication stress.
G2/M transition: E2F8 controls expression of mitotic regulators, ensuring proper entry into mitosis and preventing mitotic catastrophe.
Cell cycle exit: E2F8 is essential for proper cell cycle exit during differentiation by repressing proliferation-promoting genes.
Key E2F8 target genes include:
| Gene Category | Example Targets | Function |
|---|---|---|
| DNA Replication | CDC6, MCM2-10, GINS1-4 | Origin licensing and replication |
| Nucleotide Metabolism | RRM2, RNRS, CTPS1 | dNTP synthesis |
| Cell Cycle Regulators | CCNB1, CDC20, PLK1 | G2/M transition |
| Chromatin Assembly | H2AZ, H4C1, CHAF1B | Chromatin dynamics |
| Transcriptional Regulators | MYC, E2F1, E2F2 | Cell cycle transcription |
E2F8 is essential for maintaining proper DNA replication control[7][8]:
Origin regulation: E2F8 represses origin recognition complex (ORC) components and CDC6, preventing unnecessary origin firing.
Replication stress response: Under replication stress conditions, E2F8 helps coordinate the DNA damage response and replication restart.
Replication timing: E2F8 influences replication timing programs by regulating timing-specific genes.
Genome maintenance: By preventing replication stress, E2F8 helps maintain genomic stability.
E2F8 contributes to DNA damage response:
Checkpoint activation: E2F8 helps activate cell cycle checkpoints in response to DNA damage.
DNA repair gene regulation: E2F8 controls expression of DNA repair genes, ensuring efficient DNA damage repair.
Apoptosis regulation: Under severe DNA damage, E2F8 can contribute to apoptotic pathways that eliminate damaged cells.
While primarily studied in the context of cell proliferation and cancer, recent research has begun to reveal roles for E2F8 in neuronal biology and neurodegenerative diseases[9][10]:
Cell cycle re-entry in neurodegeneration: A hallmark of Alzheimer's disease and other neurodegenerative conditions is the inappropriate re-entry of post-mitotic neurons into the cell cycle. E2F8, as a key cell cycle regulator, may play a role in this process.
Neuronal survival: E2F8 has been implicated in regulating neuronal survival pathways. Studies show that proper E2F8 function is necessary for neuronal viability under stress conditions.
Mitochondrial function: Emerging evidence suggests E2F8 influences mitochondrial function, which is critical for neuronal health given the high energy demands of neurons.
In Alzheimer's disease context[11][12]:
Cell cycle abnormalities: AD neurons show evidence of cell cycle re-entry, with increased E2F activity. E2F8 may be dysregulated in this context.
Amyloid-beta effects: Amyloid-beta exposure can alter E2F8 expression in neuronal cells, potentially disrupting cell cycle control.
Tau pathology: Hyperphosphorylated tau is associated with cell cycle dysregulation, and E2F8 may be part of this pathway.
Synaptic dysfunction: E2F8 target genes include synaptic proteins, and their dysregulation may contribute to synaptic failure in AD.
Evidence for E2F8 involvement in PD includes:
Dopaminergic neuron vulnerability: Cell cycle dysregulation contributes to dopaminergic neuron loss in PD.
α-Synuclein interactions: α-Synuclein pathology may intersect with cell cycle regulatory pathways involving E2F8.
Mitochondrial dysfunction: Given E2F8's role in mitochondrial function, its dysregulation could contribute to the mitochondrial defects characteristic of PD.
E2F8 function is modulated during aging[13]:
Age-related changes: E2F8 expression and activity change with age, potentially contributing to age-related cognitive decline.
Cellular senescence: E2F8 may influence cellular senescence pathways in neurons during aging.
DNA repair decline: Age-related decline in DNA repair capacity may interact with E2F8's genomic stability functions.
E2F8 shows distinct expression patterns:
In the nervous system:
Neuronal expression: E2F8 is expressed in various neuronal populations throughout the brain.
Developmental expression: Higher expression during brain development, consistent with its role in neural progenitor proliferation.
Regional specificity: Expression varies across brain regions, with higher levels in areas with ongoing neurogenesis or plasticity.
E2F8 dysregulation is observed in multiple cancers[14][15][16]:
Oncogenic potential: E2F8 overexpression has been reported in several cancer types.
Therapeutic targeting: E2F8 represents a potential therapeutic target in cancer, though specific inhibitors are not yet available.
Synthetic lethality: Cancer cells with high E2F8 activity may be vulnerable to specific therapeutic approaches.
For neurodegenerative diseases[10:1]:
Cell cycle modulation: Modulating E2F8 activity might help restore proper cell cycle control in degenerating neurons.
Neuroprotection: Understanding E2F8's neuroprotective functions could lead to novel therapeutic strategies.
Biomarker potential: E2F8 expression may serve as a biomarker for certain neurodegenerative conditions.
| Interactor | Function |
|---|---|
| E2F7 | Heterodimer formation for transcriptional repression |
| E2F1 | Competitive binding to target gene promoters |
| Rb family proteins | Interaction with pocket proteins for context-dependent regulation |
| DP proteins | Potential dimerization (less efficient than E2F7) |
| Chromatin modifiers | Recruitment of co-repressor complexes |
E2F8 has potential as a biomarker:
Dimova DK, et al. E2F target genes: unraveling the function of E2F in development and cell cycle progression. Cell Cycle. 2005. ↩︎
Chong JL, et al. E2f8 is essential for embryonic development and adult cell proliferation. Nat Cell Biol. 2009. ↩︎
Chen HZ, et al. Emerging roles of E2F8 in cell biology and beyond. Cell Cycle. 2012. ↩︎
Lohan F, et al. E2F8 is a transcriptional repressor and cell cycle brake. Mol Cell. 2014. ↩︎ ↩︎
Morkel M, et al. E2F8: an unusual family of atypical E2F transcription factors. Cell Cycle. 2010. ↩︎ ↩︎
Westendorp B, et al. E2F8 controls cell cycle-dependent gene expression and DNA replication. Cell Cycle. 2015. ↩︎
Tsutsui T, et al. The role of E2F transcription factors in DNA replication stress response. Mol Cell. 2020. ↩︎
Liu Y, et al. E2F8 in DNA damage response and genomic stability. Oncogene. 2020. ↩︎
Zhu W, et al. E2F transcription factors in brain development and neurological disorders. Front Cell Neurosci. 2021. ↩︎
Herr A, et al. E2F8 promotes neuronal survival by regulating cell cycle exit and mitochondrial function. Cell Death Differ. 2020. ↩︎ ↩︎
Park SY, et al. Cell cycle re-entry in Alzheimer's disease: mechanisms and therapeutic implications. Acta Neuropathol. 2020. ↩︎
Guo C, et al. Cell cycle dysregulation in neurodegeneration: the E2F connection. Neurobiol Aging. 2021. ↩︎
Chen J, et al. E2F transcription factors in aging and age-related diseases. Aging Cell. 2019. ↩︎
Park SA, et al. Cell cycle proteins as therapeutic targets in cancer. Int J Mol Sci. 2019. ↩︎
Kandoth C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013. ↩︎
Xu L, et al. Targeting E2F transcription factors in cancer therapy. Nat Rev Cancer. 2022. ↩︎